HC Wainwright Reaffirms Buy Rating for Can-Fite BioPharma (NYSE:CANF)

Posted by Teresa Graham on Nov 16th, 2024

HC Wainwright reissued their buy rating on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock. HC Wainwright also issued estimates for Can-Fite BioPharma’s Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at ($0.05) EPS.

CANF has been the subject of a number of other research reports. EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th. StockNews.com lowered Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th.

Get Our Latest Analysis on Can-Fite BioPharma

Can-Fite BioPharma Price Performance

Shares of CANF stock opened at $1.99 on Tuesday. The firm has a market capitalization of $7.04 million, a PE ratio of -1.11 and a beta of 1.39. Can-Fite BioPharma has a 1-year low of $1.83 and a 1-year high of $4.69. The business’s fifty day moving average price is $2.25 and its 200 day moving average price is $2.52.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.